4.8.2.4Vertical
Structural Heart Devices
TAVR valves, mitral repair devices, and LAA occluders.
Market snapshot
These figures describe Cardiovascular Devices (4.8.2), the segment that Structural Heart Devices sits within — not Structural Heart Devices on its own.
- Market size
- ~$40B
- Growth
- ~3.7%CAGR (2017–22, nominal)
- Companies
- ~900
FragmentationConsolidatedEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 334510 (Electromedical & Electrotherapeutic Apparatus) — broad, also covering neuromodulation and other electromedical devices.
Business model & economics
Revenue model
Implant and device sales plus procedure-driven consumables
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 20–30%
- Capex intensity
- High
procedure and replacement-driven
Characteristics
- Structural heart (TAVR) and EP are the growth frontiers.
- Aging demographics and minimally invasive shifts drive demand.
- Dominated by Medtronic, Abbott, Boston Scientific, Edwards.
M&A deal context
Deal activityHigh
Who’s acquiring
- Cardiovascular-device strategics
- Diversified medtech platforms
- VC-backed innovators
What’s driving deals
- Acquisition of structural-heart and EP innovation.
- Aging-demographic and procedure-shift demand.
- Pulsed-field ablation and next-gen EP competition.
Find Structural Heart Devices acquisition targets
Search Acquisera’s index for companies classified under Structural Heart Devices (4.8.2.4) and build a targeted deal pipeline.
Search companies